Table 3.

Viral subtype, coreceptor usage, and infectivity reduction by CCR5 specific Igs from LTNP

Coreceptor usage
IC50/IC90, μg/mL
Viruses
Strain
4
11
20
21
22
152
110
173
NY4
NY6
NY9
NY10
HC*
HIV-36   B   R5   0.85/> 2   0.64/> 2   0.42/> 2   0.27/1.8   0.42/> 2   ND   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 45/> 45  
HIV-40   B   R5   0.51/> 2   0.60/> 2   0.96/1.7   0.28/1.9   0.46/1.5   ND   ND   ND   0.89/> 2   0.88/> 2   0.56/> 2   1.4/> 2   > 45/> 45  
92BR025   C   R5   ND   ND   0.45/> 2   1.9/> 2   0.8/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
92TH007   A   R5   ND   ND   0.01/> 2   2/> 2   0.7/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
HIV-45   B   X4, R5, R3   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   ND   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 45/> 45  
HIV-26   B   X4   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
SOS/HIV   JRFL   R5   0.5/2.9   1.1/6.1   0.4/2.2   0.6/3.3   0.8/4.4   1.2/6.7   1.3/7.2   1/5.9   ND   ND   ND   ND   > 45/> 45  
SOS/VSV-G
 		 NA
 		 NA
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 ND
 		 ND
 		 ND
 		 ND
 		 > 45/> 45
 
Coreceptor usage
IC50/IC90, μg/mL
Viruses
Strain
4
11
20
21
22
152
110
173
NY4
NY6
NY9
NY10
HC*
HIV-36   B   R5   0.85/> 2   0.64/> 2   0.42/> 2   0.27/1.8   0.42/> 2   ND   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 45/> 45  
HIV-40   B   R5   0.51/> 2   0.60/> 2   0.96/1.7   0.28/1.9   0.46/1.5   ND   ND   ND   0.89/> 2   0.88/> 2   0.56/> 2   1.4/> 2   > 45/> 45  
92BR025   C   R5   ND   ND   0.45/> 2   1.9/> 2   0.8/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
92TH007   A   R5   ND   ND   0.01/> 2   2/> 2   0.7/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
HIV-45   B   X4, R5, R3   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   ND   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   > 2/> 2   > 45/> 45  
HIV-26   B   X4   ND   ND   > 2/> 2   > 2/> 2   > 2/> 2   ND   ND   ND   ND   ND   ND   ND   > 45/> 45  
SOS/HIV   JRFL   R5   0.5/2.9   1.1/6.1   0.4/2.2   0.6/3.3   0.8/4.4   1.2/6.7   1.3/7.2   1/5.9   ND   ND   ND   ND   > 45/> 45  
SOS/VSV-G
 		 NA
 		 NA
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 > 10/> 10
 		 ND
 		 ND
 		 ND
 		 ND
 		 > 45/> 45
 

The values are expressed as Ig concentration (μg/mL) inhibiting 50% (IC50) and 90% (IC90) virus replication. The results are representative of 3 independent experiments. Six primary isolates were used to infect PBMCs from HCs, and 2 viral molecular clones (SOS/HIV/JRFL and an HIV-unrelated clone SOS/VSV-G) were used to infect CCR5-U87 cells.

ND indicates not done; NA, not applicable.

*

A pool of total serum Ig from 5 HCs was used as negative control (HC). The highest Ig concentration tested in neutralization assay was 45 and 10 μg/mL for HCs and LTNsP, respectively.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal